Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | PTGIR | P43119 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423804 | 1.00 | PPARG (0.51) | PPARGPPARAPTGIRPPARDPTGDR2 | |
| SCHEMBL5422007 | 0.87 | PPARG (0.49) | PPARGPPARAPPARDRXRARXRB | |
| SCHEMBL5422006 | 0.87 | PPARG (0.49) | PPARGPPARAPPARDRXRARXRB | |
| SCHEMBL5427399 | 0.85 | PPARA (0.46) | PPARGPPARAPPARDGAALMNA | |
| SCHEMBL5427391 | 0.85 | PPARA (0.46) | PPARGPPARAPPARDGAALMNA | |
| SCHEMBL5427796 | 0.84 | PPARG (0.51) | PPARGPPARAPPARDRXRARXRB | |
| SCHEMBL5414621 | 0.84 | PPARG (0.51) | PPARGPPARAPPARDRXRARXRB | |
| SCHEMBL5414627 | 0.84 | PPARG (0.51) | PPARGPPARAPPARDRXRARXRB | |
| SCHEMBL5419513 | 0.81 | FFAR1 (0.46) | PPARGPPARAPPARDRXRARXRB | |
| SCHEMBL5419520 | 0.81 | FFAR1 (0.46) | PPARGPPARAPPARDRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167490-A1 | Imino ether derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO LTD | 2007-07-19 | — | — | US | disclosed |
| EP-1602642-A1 | IMINO ETHER DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167490-A1 | Imino ether derivative compounds and drugs containing the compounds as the active ingredient | INSR, NR1H2, NR1H3 | PPARG 18/4885PPARA 14/4885PTGIR 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.